Immunoengineering and Biomaterial-Based Strategies for Transplant Tolerance

Achieving durable allograft acceptance while minimizing the burden of chronic immunosuppression remains a central challenge in transplantation. Advances in immunoengineering, from nanoparticle systems to biomaterial-based delivery platforms, now offer precise routes to modulating the alloimmune response, enabling immunomodulators to reach the specific lymphoid tissues where tolerance is established or lost.

This Research Topic brings together studies on immunoengineering and biomaterial-based strategies designed to modulate alloimmunity and promote transplant tolerance. We welcome submissions on:

Nanoparticle, hydrogel, and other biomaterial-based delivery platforms (e.g., MECA-79-coated systems and beyond) for costimulatory blockade agents or other immunomodulators;
Engineered or cell-based delivery approaches, including exosome- and scaffold-based systems, for modulating regulatory and effector T-cell responses;
Interactions between engineered delivery platforms and stromal cell populations, including fibroblastic reticular cells, within the lymphoid microenvironment;
Combination and synergistic strategies pairing immunoengineering or biomaterial-based approaches with conventional immunosuppressive regimens to enhance allograft survival.
We invite original research, reviews, mini reviews, and perspectives that advance the design, mechanistic understanding, or translational application of engineering-based approaches to allograft survival.

This Research Topic is aimed at immunoengineers, biomaterials scientists, nanotechnologists, transplant immunologists, and translational researchers working at the interface of drug delivery and transplantation medicine.